86 results on '"Libe, Rossella"'
Search Results
52. DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer
53. Molecular classifiers refine the prognostic stratification of adrenocortical carcinoma
54. Molecular classification of benign adrenocortical tumors: an integrated genomic study
55. Genetics of Primary Bilateral Macronodular Adrenal Hyperplasia: when and what to test
56. Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma
57. Chapter 15 - Genetics of Adrenocortical Tumors (ACT) and Hypersecretory Syndromes
58. Outcome of patients with adrenocortical cancer after discontinuation of adjuvant mitotane therapy
59. Targeted molecular markers derived from genomic classification for adrenocortical cancer prognostication
60. Successful response to pegylated interferon alpha in a patient with recurrent paraganglioma
61. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer
62. Adrenocortical carcinoma
63. DNA methylation is an independent prognostic marker of survival in adrenocortical cancer
64. Focal DNA methylation measurement in adrenocortical carcinoma is a prognostic marker independent from tumor stage and Ki67; an ENSAT study
65. Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors.
66. PRKACA defects and cortisol-producing lesions of the adrenal cortex: specific clinical phenotypes and histological features
67. Functional study of ARMC5 (armadillo repeat containing 5), a new tumour suppressor gene involved in primary bilateral macronodular adrenal hyperplasia
68. Chapter 16 - Genetics of Adrenocortical Tumors (ACT) and Hypersecretory Syndromes
69. Prognostic factors of overall survival of stage III or IV adrenocortical carcinomas (ACC): A multicenter ENS@T study.
70. Prognostic value of DNA methylation in adrenocortical carcinomas: an ENSAT study
71. Armadillo repeat containing 5 gene (ARMC5) alterations in a large cohort of 98 ACTH-independant macronodular adrenal hyperplasia (AIMAH) patients: genotype/phenotype correlations.
72. Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors
73. List of Contributors
74. Molecular screening for personalized treatment approach in advanced adrenocortical cancer
75. Prognostic factors of advanced unresectable by stage III and IV ENS@T adrenocortical carcinomas (ACC)
76. Recurrence of a Pheochromocytoma With TNEM127 Mutation Negative on 18F-FDOPA and 18F-FDG but Positive on 123I-MIBG and 68Ga-DOTATOC Imaging.
77. Adrenocortical Tumors
78. Functional Phosphodiesterase 11A Mutations May Modify the Risk of Familial and Bilateral Testicular Germ Cell Tumors
79. Loss of Heterozygosity of 17p13, With Possible Involvement of ACADVL and ALOX15B, in the Pathogenesis of Adrenocortical Tumors
80. Activities of 21-hydroxylase, 17&agr;-hydroxylase and 17,20-lyase.
81. Recurrence of a Pheochromocytoma With TNEM127 Mutation Negative on 18F-FDOPA and 18F-FDG but Positive on 123I-MIBG and 68Ga-DOTATOC Imaging.
82. DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer.
83. [Adrenocortical carcinoma and pregnancy].
84. Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE.
85. [Adrenal cortical carcinoma: advances in the pathophysiology and management of this malignancy].
86. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.